DEF: Exelixis Reports Strong 2024 Performance and Outlines 2025 Priorities

Exelixis reports a productive 2024 with cabozantinib franchise growth and advancements in zanzalintinib development, setting the stage for multiple pivotal data readouts in 2025.

Summary

• Exelixis had a highly productive year in 2024, with the cabozantinib franchise growing approximately 11% year over year in demand, new patient starts, and revenue.
• U.S. net product revenues (NPR) for cabozantinib reached $1.8 billion in fiscal year 2024, while global NPR generated by Exelixis and its partners totaled $2.5 billion.
• The company significantly advanced the development of zanzalintinib and its pipeline, anticipating multiple pivotal data readouts, pipeline data presentations, and Investigational New Drug filings in 2025.
• The Board of Directors welcomed new independent directors, Mary C. Beckerle, Ph.D., and S. Gail Eckhardt, M.D., in January 2024.
• The Board worked with management to ensure good stewardship of capital, including expense management and share repurchase initiatives, while maintaining R&D investment.
• Exelixis is confident in its position to capitalize on opportunities and generate long-term value for stakeholders based on its progress in 2024 and plans for 2025.
• The 2025 Annual Meeting of Stockholders will be held virtually on Wednesday, May 28, 2025, at 9:00 a.m. Pacific Time.
• The Board recommends voting FOR Proposal Nos. 1-3 identified in the proxy statement.
• The company intends to mail the Notice of Internet Availability of Proxy Materials relating to the Annual Meeting on or about April 16, 2025.
• The company has engaged Innisfree M&A Incorporated to assist in the solicitation of proxies from shareholders for a fee of $25,000 plus reimbursement of customary out-of-pocket expenses.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results, pipeline advancements, and strategic initiatives. The tone is optimistic and confident, reflecting a well-managed and growing company.

Positives

• Strong growth of the cabozantinib franchise.
• Advancement of zanzalintinib development.
• Addition of experienced independent directors to the Board.
• Good stewardship of capital through expense management and share repurchase initiatives.
• Successful resolution of MSN II district court litigation securing cabozantinib patent estate, resulting in a loss of exclusivity for cabozantinib no earlier than 2030.
• The company received U.S. FDA Approval of CABOMETYX (cabozantinib) for the treatment of adult and pediatric patients 12 years of age or older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pNET and epNET.

Negatives

• No negative aspects were explicitly mentioned in the document.

Risks

• The document contains forward-looking statements that involve risks and uncertainties, including market acceptance of products, effectiveness of products compared to competitors, costs associated with commercialization and R&D, potential failure of product candidates in clinical testing, dependence on collaboration partners, regulatory review processes, compliance with legal requirements, adverse safety events, dependence on third-party vendors, protection of intellectual property rights, market competition, and changes in economic and business conditions.

Future Outlook

Exelixis anticipates multiple pivotal data readouts for zanzalintinib in 2025, along with pipeline data presentations and Investigational New Drug filings, positioning zanzalintinib as the next franchise opportunity.

Management Comments

• Exelixis' mission is to help cancer patients recover stronger and live longer.
• The company's objective is the development of a pipeline of innovative product candidates with the potential to be the first and/or best in their respective therapeutic classes.
• The Board seeks to provide the right mix of effective governance, oversight and support so that the Exelixis team can flourish.
• Based on the company's progress throughout 2024 and its plans for 2025, we are confident that Exelixis is well positioned to take advantage of its many opportunities and generate long-term value for its stakeholders.

Industry Context

Exelixis operates in the competitive biopharmaceutical industry, specifically in the oncology space. The company's success depends on its ability to innovate and commercialize new cancer therapies, as well as maintain its market share in existing products like cabozantinib. The document highlights the company's efforts to expand its pipeline and explore new therapeutic areas, which is a common strategy among biopharmaceutical companies to mitigate risks and drive long-term growth.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or benchmarks.
• However, it mentions that the Compensation Committee uses a peer group of companies to benchmark executive compensation.
• The peer group includes companies such as ACADIA Pharmaceuticals Inc., Horizon Therapeutics plc, and Incyte Corporation, which are all publicly-traded, U.S.-based biotechnology/pharmaceutical companies with a focus on oncology.

Management Changes

Corporate Governance

Legal Proceedings

• The company successfully resolved the second Abbreviated New Drug Application against MSN Pharmaceuticals, securing the cabozantinib patent estate with a loss of exclusivity no earlier than 2030.

Related Party Transactions

• BlackRock, Inc., a greater than 5% holder of our common stock, managed a portion of our cash and investments portfolio. We incurred $0.3 million in fees for BlackRock advisory services performed during the year ended January 3, 2025.

Stakeholder Impact

• Shareholders: Potential for long-term value generation through pipeline advancements and strategic initiatives.
• Patients: Access to innovative cancer medicines and improved standards of care.
• Employees: Opportunities for career development and participation in a culture of belonging.
• Community: Engagement with philanthropic organizations and support for cancer care, education, and advocacy.

Next Steps

• Participation in the 2025 Annual Meeting of Stockholders on May 28, 2025.
• Continued development and commercialization of cabozantinib.
• Advancement of zanzalintinib and other product candidates through clinical trials.
• Potential Investigational New Drug filings in 2025.
• Evaluation of strategic business development opportunities.

Key Dates

Keywords

Exelixis, cabozantinib, zanzalintinib, Annual Meeting, Board of Directors, financial results, oncology, pharmaceutical, clinical trials, executive compensation, corporate governance